Watch Live

Tweet TWEET

Zacks Analyst Blog Highlights: Ambac, Onyx Pharmaceuticals,

Pfizer and Wyeth 
CHICAGO--(BUSINESS WIRE)--March 06, 2008
Zacks.com announces the list of stocks featured in the Analyst
Blog. Every day the Zacks Equity Research analysts discuss the latest
news and events impacting stocks and the financial markets. Stocks
recently featured in the blog include: Ambac Financial Group, Inc.
(NYSE: ABK), Onyx Pharmaceuticals (Nasdaq: ONXX), Pfizer (NYSE: PFE)
and Wyeth (NYSE: WYE). 
See the latest posts to the Analyst Blog here:
http://www.zacks.com/blog/post_info.html?g=6 
Here are highlights from Wednesday's Analyst Blog: 
Breaking Down Ambac's News 
Earlier today, Ambac Financial Group, Inc. (NYSE: ABK) announced
it would sell at least $1.5 billion in stock and convertible
securities to help boost capital levels at its main insurance unit,
which has been facing potential ratings downgrades. While this move
should help to retain its current credit rating presently, it is
abundantly clearly the market was not pleased. 
- By selling $1.0 billion in new shares (using $10 per share), ABK
would substantially dilute its shares outstanding -- basically a
doubling. 
- Considering that we are at the beginning of mortgage meltdown
versus the trough, we view the $1.5 billion in additional capital as
more of a "Band-aid effect" to the problem. 
- ABK is also attempting to shore up its capital base by
suspending new business in the riskiest segment of the market. While
capital may improve from this action over time, earnings will be
hampered over the near-term. 
We rate the share of ABK a Sell. Our six-month target price is
currently $7.65. 
Downgrading Onyx Pharma to a Hold 
Onyx Pharmaceuticals (Nasdaq: ONXX) lost one key near-term
catalyst due to the early termination of its phase III ESCAPE trial of
Nexavar for lung cancer on Feb 18, 2008. The failure also cast shadow
for Nexavar's long-term potential. Although worldwide Nexavar sales
continued growth in 4Q07, U.S. sales has been under great pressure due
to heavy competition in the kidney cancer market. 
We believe Nexavar sales will continue to grow over the next
several years since the label has expanded to liver cancer, but the
potential has been limited without the indications of lung cancer and
melanoma. Therefore, we maintain our Hold rating on Onyx shares with a
price target of $31. 
Although worldwide Nexavar sales continued its momentum in the
fourth quarter of 2007, we see increase pressure on US sales of the
drug in the U.S. kidney market. Competition is heavy and comes from
Pfizer's (NYSE: PFE) Sutent and Wyeth's (NYSE: WYE) Torisel. 
About Zacks Equity Research 
Zacks Equity Research provides the best of quantitative and
qualitative analysis to help investors know what stocks to buy and
which to sell for the long-term. 
Continuous coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them
keen insights to developments that affect company profits and stock
performance. Recommendations and target prices are six-month time
horizons. 
Zacks "Profit from the Pros" e-mail newsletter provides highlights
of the latest analysis from Zacks Equity Research. Subscribe to this
free newsletter today: http://at.zacks.com/?id=2677 
About Zacks 
Zacks.com is a property of Zacks Investment Research, Inc., which
was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew
he could find patterns in stock market data that would lead to
superior investment results. Amongst his many accomplishments was the
formation of his proprietary stock picking system; the Zacks Rank,
which continues to outperform the market by nearly a 3 to 1 margin.
The best way to unlock the profitable stock recommendations and market
insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your
free subscription to Profit from the Pros. 
The performance of the Zacks Rank portfolios for annual and
year-to-date periods are the linked monthly total returns (price
changes + dividends) of equal weighted hypothetical portfolios,
consisting of those stocks with the indicated Zacks Rank, assuming
monthly rebalancing and zero transaction costs. These are not the
returns of actual portfolios. The hypothetical portfolios were created
at the beginning of each month from January 1988 forward based on the
values of the Zacks Rank available to Zacks' clients before the
beginning of each month. The portfolios created monthly from 1988
through September 2006 exclude ADRs and are comprised of stocks that
have the indicated Zacks Rank and were covered by at least two
analysts at the time of the stocks inclusion in the portfolio.
Starting in October 2006 and going forward, the portfolios are
comprised of all stocks with the indicated Zacks Rank and do not
exclude ADRs, which is more reflective of the list of stocks that
customers will find on the Zacks web sites. These performance numbers
have been audited from 1995 through 2003 by Virchow, Krause & Company,
LLP. 
Visit http://www.zacks.com/performance for information about the
performance numbers displayed in this press release. 
Disclaimer: Past performance does not guarantee future results.
Investors should always research companies and securities before
making any investments. Nothing herein should be construed as an offer
or solicitation to buy or sell any security. 
CONTACT:
Zacks.com
Terry Ruffolo
Media Relations
312-265-9213
Visit: www.zacks.com
 
 
Press spacebar to pause and continue. Press esc to stop.